Bausch + Lomb Corporation (BLCO) Stock Analysis
Range Bound setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Analyst target reached at $16.21 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single source or limited number of sources.
Bausch + Lomb is a fully integrated global eye health company with approximately 400 products across Vision Care, Pharmaceuticals, and Surgical segments, operating in approximately 100 countries with approximately 13,000 employees. Approximately 88% owned by Bausch Health... Read more
Sell if holding. Analyst target reached at $16.21 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single source or limited number of sources. Chart setup: RSI 44 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 4/6 gates (clean insider activity, no SEC red flags, earnings proximity 89d clear, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersingle source or limited number of sources10-K Item 1A: 'Certain of our products or components thereof are available from a single source or a limited number of sources'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $16.21 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Supplier: single source or limited number of sources. Chart setup: RSI 44 mid-range, Bollinger mid-band. Prior stop was $15.29. Score 5.3/10, moderate confidence.
Take-profit target: $16.78 (+3.4% upside). Prior stop was $15.29. Stop-loss: $15.29.
Concentration risk — Supplier: single source or limited number of sources; Analyst target reached - limited upside remaining; Consecutive earnings misses (2).
Bausch + Lomb Corporation trades at a P/E of N/A (forward 15.0). TrendMatrix value score: 6.7/10. Verdict: Sell.
19 analysts cover BLCO with a consensus score of 3.6/5. Average price target: $18.
What does Bausch + Lomb Corporation do?Bausch + Lomb is a fully integrated global eye health company with approximately 400 products across Vision Care,...
Bausch + Lomb is a fully integrated global eye health company with approximately 400 products across Vision Care, Pharmaceuticals, and Surgical segments, operating in approximately 100 countries with approximately 13,000 employees. Approximately 88% owned by Bausch Health Companies Inc., with active separation process ongoing.